The percentage on each card is ANNX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● GlobeNewsWireNov 17, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im…
● GlobeNewsWireNov 9, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q…
Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug
Annexon (NASDAQ: ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026. The company is te…
● GlobeNewsWireOct 28, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im…
● GlobeNewsWireOct 16, 2026 · 17:34 ETCOMPANY'S OWN WORDS
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im…
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Annexon targets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash runway into 2028, su…
● GlobeNewsWireSep 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demon…
● GlobeNewsWireSep 16, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that i…
● GlobeNewsWireSep 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Annexon to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that i…
Article counts from the last market-wide feed page, across every symbol we track and not just ANNX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.